Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05107739 · ClinicalTrials.gov registry record · Phase 1
A Study of DeTIL-0255 in Adults With Advanced Malignancies
A Phase 1 study, sponsored by Nurix Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT05107739 is a Phase 1 study that was terminated before completion, run by Nurix Therapeutics. The registered enrollment target is 5 participants.
The verdict
NCT05107739, a Phase 1 study, was terminated before completion, sponsored by Nurix Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a first-in-human Phase 1 multicenter, open-label oncology study designed to evaluate the safety and efficacy of NX-DeTIL-0255-201 in patients with advanced malignancies.
Interventions
- BIOLOGICAL Drug Product De-TIL-0255
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-12-22 |
| Est. Completion | 2023-05-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05107739
The ClinicalTrials.gov registry entry for NCT05107739 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nurix Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Drug Product De-TIL-0255 is the first listed.
NCT05107739 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05107739 about?
NCT05107739 is a clinical study titled "A Study of DeTIL-0255 in Adults With Advanced Malignancies". This is a first-in-human Phase 1 multicenter, open-label oncology study designed to evaluate the safety and efficacy of NX-DeTIL-0255-201 in patients with advanced malignancies.
What is the current status of trial NCT05107739?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2021-12-22. Estimated completion is 2023-05-09.
What interventions are being tested in trial NCT05107739?
The interventions under investigation include: Drug Product De-TIL-0255 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05107739?
This trial is sponsored by Nurix Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.